QIAGEN N.V. announced a joint press release regarding a planned tender offer by Crown NL Bidco B.V. to acquire all issued ordinary shares of the company at €46.50 per share in cash, pursuant to a Business Combination Agreement dated October 21, 2026. The offer is subject to customary conditions, including regulatory approvals and shareholder consent at an extraordinary general meeting. QIAGEN's boards have unanimously recommended the transaction as fair from a financial perspective. QIAGEN N.V. develops molecular diagnostics and life science tools for clinical research and infectious disease testing.
